title: Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors.
abstract: Immunological recognition of transformed cells is critically important to limit tumor development and proliferation. Because established tumors have escaped immune recognition and elimination, novel strategies to enhance antitumor immunity have been developed. A unique approach has used the introduction of genes encoding major histocompatibility complex (MHC) antigens into tumor cells. Experiments in mice have shown that the expression of syngeneic class II MHC antigens in tumor cells completely abrogates tumorigenicity and induces tumor-specific immunity. In this study we sought to determine whether a more effective antitumor immune response would be generated by introducing xenogeneic class II MHC genes into tumor cells. To address this question we used recombinant retroviruses to express human class II MHC genes in a highly malignant murine neuroblastoma cell line, Neuro-2a. We found that normal mice inoculated with Neuro-2a expressing the human class II MHC antigen did not develop tumors and were immune to subsequent challenge with unmodified Neuro-2a cells. In addition, mice bearing small established Neuro-2a tumors were cured by vaccination with Neuro-2a expressing human class II MHC. We hypothesize that a similar approach using retroviral-mediated transduction of class II MHC genes into human tumor cells may be an effective alternative to current cancer treatment.
authors.affiliation: Herman B. Wells Center for Pediatric Research, Riley Hospital for Children, Indianapolis, IN 46202-5225, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Hock
authors.forename: B D
authors.initials: BD
authors.lastname: Reynolds
authors.forename: C L
authors.initials: CL
authors.lastname: Tucker-McClung
authors.forename: W W
authors.initials: WW
authors.lastname: Kwok
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D004195:Disease Models, Animal; D005802:Genes, MHC Class II; D006681:HLA-D Antigens / Q000032:analysis; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D051379:Mice; D009447:Neuroblastoma / Q000235:genetics* / Q000556:secondary / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014162:Transfection / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D006681:HLA-D Antigens